Shandong Xinhua Pharmaceutical Wins NMPA Approval for Phloroglucinol Injection

Claim 70% Off TipRanks This Holiday Season

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

An announcement from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) is now available.

Shandong Xinhua Pharmaceutical Company Limited has obtained a Drug Registration Certificate from China’s National Medical Products Administration for its Phloroglucinol Injection, a prescription chemical drug used to treat acute spasmodic pain related to digestive and biliary tract dysfunctions, urethral, bladder and kidney colic, and gynecological spasmodic pain. The approval, following the submission and review of marketing application materials since July 2024, enables the company to move toward commercial production and sale of the injection once it meets pharmaceutical production quality management standards, potentially enhancing its product portfolio in the domestic pain-management and antispasmodic treatment segment.

More about Shandong Xinhua Pharmaceutical Company Limited Class H

Shandong Xinhua Pharmaceutical Company Limited is a PRC-based pharmaceutical manufacturer listed in Hong Kong, focusing on the development, production and sale of chemical drugs. The company’s portfolio includes prescription medicines targeting various therapeutic areas for the domestic Chinese market and potentially for broader distribution as products obtain regulatory approvals.

Average Trading Volume: 2,146,783

Technical Sentiment Signal: Buy

Current Market Cap: HK$9.98B